Medindia

X

Milestone Scientific Announces 2007 Year-End Results

Tuesday, April 1, 2008 General News J E 4
Advertisement
LIVINGSTON, N.J., March 31 Milestone Scientific,Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injectiontechnologies, today reported its operational and financial results for its2007 fiscal year, ended December 31, 2007.

Joe W. Martin, Chief Executive Officer of Milestone, stated, "Lookingahead, our focus in 2008 will be largely centered on increasing sales of theSTA System, both domestically and internationally, as well as supporting salesof our legacy CCLAD system, CompuDent, and driving recurring orders of thedisposable hand pieces used in conjunction with both instruments. Thechallenge going forward will be leveraging creative and tactical advertisingand proactive marketing strategies to spread the 'right' message about the STASystem to each and every dentist."

Continuing, Martin added, "Worldwide, we estimate that over 35 milliondental injections have been administered to patients with either the STA orCompuDent systems, to date. Moreover, our patented CompuFlo technology,embedded in the STA System, has been the subject of more than 50 publicationsvalidating the efficacy and safety of the technology in a wide range ofmedical injection applications. In 2008, we will accelerate our pursuit ofcollaborative opportunities with medical, pharmaceutical and healthcarecompanies interested in developing new product applications using CompuFlo, inorder to build and grow long term shareholder value in Milestone."

"Although there is still a lot of work to do, I believe that Milestone iswell positioned to begin demonstrating much improved sales growth from ourexisting product line as our new marketing messages take hold and our marketpenetration efforts gain greater traction. Moreover, our results-driven gameplan for leveraging CompuFlo to introduce innovative new products to themedical industry should provide us with ample opportunities to seek trulydynamic growth in the future," concluded Martin.

The Company will host a teleconference on Tuesday, April 1, 2008,beginning at 9:30 AM Eastern Daylight Time, and invites all interested partiesto join management in a discussion regarding the Company's financialperformance, corporate progress and other meaningful developments. Theconference call can be accessed by dialing toll-free 800-257-7087. For thoseunable to participate at that time, a replay of the teleconference can beaccessed domestically by dialing 800-405-2236 and enter the passcode11111518#. The replay will be available for 90 days.

About Milestone Scientific, Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engagedin pioneering proprietary, highly innovative technological solutions for themedical and dental markets. Central to the Company's IP platform and productdevelopment strategy is its patented CompuFlo(R) technology for the improvedand painless delivery of local anesthetic. Specifically, CompuFlo is acomputer-controlled, pressure sensitive infusion, perfusion, suffusion andaspiration technology, which provides real-time readouts of pressures, fluiddensities and flow rates, enabling the advanced delivery and removal of a widearray of fluids. The award-winning STA(TM) System is a patented Computer-Controlled Local Anesthesia Delivery (CCLAD) system which uses this technologyand provides dentists with audible and visual signals as to in-tissuepressure. Milestone's existing painless injection systems are currently soldin 25 countries. For more information on these and other innovative Milestoneproducts, please visit the Company's web site found at www.milesci.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding thetiming and financial impact of the Milestone's ability to implement itsbusiness plan, expected revenues and future success. These statements involvea number of risks and uncertainties and are based on ass
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 F...
S
Gamma Secretase Modulators Show Promise in Alzheim...